BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Although vascular occlusive events were rarely reported during the initial development of second-generation BCR::ABL1 TKIs, a meta-analysis found that these events occurred in 5.9% of patients with CML treated with these agents, including bosutinib, dasatinib, nilotinib, and ponatinib [13].